中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2014年
22期
4006-4009
,共4页
肺炎%CD4阳性T淋巴细胞%CD8阳性T淋巴细胞%CD4-CD8比值%C反应蛋白质%芝胞内糖肽
肺炎%CD4暘性T淋巴細胞%CD8暘性T淋巴細胞%CD4-CD8比值%C反應蛋白質%芝胞內糖肽
폐염%CD4양성T림파세포%CD8양성T림파세포%CD4-CD8비치%C반응단백질%지포내당태
Pneumonia%CD4-positive T-lymphocytes%CD8-positive T-lymphocytes%CD4-CD8 ratio%C-reactive protein%Polystictus glycopeptide
目的：探讨云芝胞内糖肽对老年肺炎临床预后的影响。方法73例在镇江市第一人民医院住院的老年肺炎患者随机分为观察组33例和对照组40例。两组患者均给予抗生素等常规治疗，治疗组患者加用云芝胞内糖肽胶囊口服治疗（每次1.0 g，每日3次），疗程10 d。两组治疗前后均检测血常规、外周血C反应蛋白（CRP）和T淋巴细胞亚群以及行X 线片检查。结果治疗10 d后，观察组的总有效率显著高于对照组（93.9%vs.72.5%，Fisher确切概率0.029）。云芝胞内糖肽能增加外周血CD4+和CD4+/CD8+比值，降低CD8+，促进血清CRP的降低（P＜0.05），并且未见不良反应。结论云芝胞内糖肽能提高老年肺炎患者的疗效、改善其预后。其机制可能与其调节T淋巴细胞亚群的功能、改善细胞免疫状态、减轻炎症反应有关。
目的：探討雲芝胞內糖肽對老年肺炎臨床預後的影響。方法73例在鎮江市第一人民醫院住院的老年肺炎患者隨機分為觀察組33例和對照組40例。兩組患者均給予抗生素等常規治療，治療組患者加用雲芝胞內糖肽膠囊口服治療（每次1.0 g，每日3次），療程10 d。兩組治療前後均檢測血常規、外週血C反應蛋白（CRP）和T淋巴細胞亞群以及行X 線片檢查。結果治療10 d後，觀察組的總有效率顯著高于對照組（93.9%vs.72.5%，Fisher確切概率0.029）。雲芝胞內糖肽能增加外週血CD4+和CD4+/CD8+比值，降低CD8+，促進血清CRP的降低（P＜0.05），併且未見不良反應。結論雲芝胞內糖肽能提高老年肺炎患者的療效、改善其預後。其機製可能與其調節T淋巴細胞亞群的功能、改善細胞免疫狀態、減輕炎癥反應有關。
목적：탐토운지포내당태대노년폐염림상예후적영향。방법73례재진강시제일인민의원주원적노년폐염환자수궤분위관찰조33례화대조조40례。량조환자균급여항생소등상규치료，치료조환자가용운지포내당태효낭구복치료（매차1.0 g，매일3차），료정10 d。량조치료전후균검측혈상규、외주혈C반응단백（CRP）화T림파세포아군이급행X 선편검사。결과치료10 d후，관찰조적총유효솔현저고우대조조（93.9%vs.72.5%，Fisher학절개솔0.029）。운지포내당태능증가외주혈CD4+화CD4+/CD8+비치，강저CD8+，촉진혈청CRP적강저（P＜0.05），병차미견불량반응。결론운지포내당태능제고노년폐염환자적료효、개선기예후。기궤제가능여기조절T림파세포아군적공능、개선세포면역상태、감경염증반응유관。
Objective To investigate effects of polystictus glycopeptide on the clinical prognosis of senile pneumonia.Methods Seventy three patients with senile pneumonia in our hospital were randomly divided into observation group (33 cases) and control group (40 cases). Patients of the two groups were treated by antibiotics and other conventional treatment. Patients of the observation group were also treated by taking polystictus glycopeptide capsule (1.0 g each time, 3 times a day). A course of treatment was 10 days. Routine blood, peripheral blood C-reactive protein (CRP) and T lymphocyte subgroup were detected, and X-ray examination was also performed in the two groups before and after the treatment.Results The total effective rate in the observation group was significantly higher than the control group after the treatment of 10 days (93.9%vs. 72.5%, Fisher's exact probability 0.029). Furthermore, our study also found that the treatment of polystictus glycopeptide increased peripheral blood CD4+ and CD4+/CD8+ ratio, reduced CD8+, and promoted the decrease of serum CRP (P<0.05), while adverse reactions were not observed.ConclusionPolystictus glycopeptide can improve the curative effect of elderly patients with pneumonia, improve their prognosis. The mechanism may be involving its effects on the regulation of the function of T lymphocyte subsets, improvement of the cellular immunity state and the reduction of inflammation reactions.
